LON:HIK - Hikma Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 1,751 +7.50 (+0.43 %) (As of 05/23/2019 08:47 AM ET)Previous CloseGBX 1,743.50Today's RangeGBX 1,736.50 - GBX 1,78052-Week RangeGBX 1,290 - GBX 2,089Volume193,877 shsAverage Volume822,138 shsMarket Capitalization£4.24 billionP/E Ratio15.03Dividend Yield2.27%BetaN/A ProfileAnalyst RatingsChartDividendInsider TradesHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals. The Generics segment develops and sells oral and other non-injectable generic products for retail market. The Branded segment develops, manufactures, and markets branded generics and in-licensed products to retail and hospital markets. The company offers products in various therapeutic areas, including respiratory, oncology, pain management, anti-infectives, cardiovascular, diabetes, and central nervous system. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom. Receive HIK News and Ratings via Email Sign-up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolLON:HIK Previous Symbol CUSIPN/A CIKN/A Webhttp://www.hikma.com/ Phone+44-20-73992760Debt Debt-to-Equity Ratio37.54 Current Ratio1.87 Quick Ratio1.17Price-To-Earnings Trailing P/E Ratio15.03 Forward P/E Ratio13.07 P/E GrowthN/A Sales & Book Value Annual Sales£2.07 billion Price / Sales2.05 Cash FlowGBX 121 per share Price / Cash Flow14.47 Book ValueGBX 698 per share Price / Book2.51Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees8,400 Outstanding Shares241,912,992Market Cap£4.24 billion Next Earnings Date8/9/2019 (Estimated) OptionableNot Optionable Hikma Pharmaceuticals (LON:HIK) Frequently Asked Questions What is Hikma Pharmaceuticals' stock symbol? Hikma Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HIK." How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals? Hikma Pharmaceuticals announced a dividend on Wednesday, March 13th. Investors of record on Thursday, April 4th will be given a dividend of GBX 0.26 per share on Wednesday, May 22nd. This represents a yield of 1.23%. The ex-dividend date of this dividend is Thursday, April 4th. This is an increase from Hikma Pharmaceuticals's previous dividend of $0.12. The official announcement can be viewed at this link. View Hikma Pharmaceuticals' Dividend History. When is Hikma Pharmaceuticals' next earnings date? Hikma Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, August 9th 2019. View Earnings Estimates for Hikma Pharmaceuticals. What price target have analysts set for HIK? 7 brokerages have issued 12-month price objectives for Hikma Pharmaceuticals' stock. Their predictions range from GBX 1,350 to GBX 2,250. On average, they anticipate Hikma Pharmaceuticals' stock price to reach GBX 1,808.57 in the next year. This suggests a possible upside of 3.3% from the stock's current price. View Analyst Price Targets for Hikma Pharmaceuticals. What is the consensus analysts' recommendation for Hikma Pharmaceuticals? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Hikma Pharmaceuticals. Has Hikma Pharmaceuticals been receiving favorable news coverage? News coverage about HIK stock has been trending positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Hikma Pharmaceuticals earned a media sentiment score of 2.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the near future. Who are some of Hikma Pharmaceuticals' key competitors? Some companies that are related to Hikma Pharmaceuticals include Aurora Cannabis (ACB), Bausch Health Companies (BHC), Evotec (EVT), Aphria (APHA), Hexo (HEXO), OrganiGram (OGI), HEXO (HEXO), Green Organic Dutchman (TGOD), CannTrust (TRST), Knight Therapeutics (GUD), Supreme Cannabis (FIRE), Flowr (FLWR), Supreme Cannabis (FIRE), HLS Therapeutics (HLS) and HLS Therapeutics (HLS). What other stocks do shareholders of Hikma Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hikma Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Gran Tierra Energy (GTE), Och-Ziff Capital Management Group (OZM) and Belden (BDC). Who are Hikma Pharmaceuticals' key executives? Hikma Pharmaceuticals' management team includes the folowing people: Mr. Said Samih Taleb Darwazah, Exec. Chairman (Age 62)Mr. Mazen Samih Taleb Darwazah, Exec. Vice Chairman & Pres of MENA (Age 61)Mr. Sigurdur Oli Olafsson Ph.D., CEO & Exec. Director (Age 50)Mr. Khalid Walid Hussni Nabilsi, Chief Financial Officer (Age 47)Dr. Surendera Tyagi, Group Chief Scientific Officer and Global Head of R&D How do I buy shares of Hikma Pharmaceuticals? Shares of HIK and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Hikma Pharmaceuticals' stock price today? One share of HIK stock can currently be purchased for approximately GBX 1,751. How big of a company is Hikma Pharmaceuticals? Hikma Pharmaceuticals has a market capitalization of £4.24 billion and generates £2.07 billion in revenue each year. Hikma Pharmaceuticals employs 8,400 workers across the globe. What is Hikma Pharmaceuticals' official website? The official website for Hikma Pharmaceuticals is http://www.hikma.com/. How can I contact Hikma Pharmaceuticals? Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company can be reached via phone at +44-20-73992760. MarketBeat Community Rating for Hikma Pharmaceuticals (LON HIK)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 610 (Vote Outperform)Underperform Votes: 451 (Vote Underperform)Total Votes: 1,061MarketBeat's community ratings are surveys of what our community members think about Hikma Pharmaceuticals and other stocks. Vote "Outperform" if you believe HIK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HIK will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/23/2019 by MarketBeat.com StaffFeatured Article: What is the Coverage Ratio? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.